1,4900
24-января-25 15:45:00
15 мин. задержка
Акции
+0,1000
+7,19%
Сегодняшний диапазон
1,3600 - 1,4900
ISIN
N/A
Источник
NASDAQ
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer
08 фев 2021 07:00:01 Источник Nasdaq GlobeNewswire